Difficulty: Medium
Average Score: 75%
Practice
If considering starting a patient on the nucleoside reverse transcriptase inhibitor abacavir, the following testing is recommended prior to prescribing:
Correct answer
B
Rationale
HLA B*5701 testing is mandatory before prescribing abacavir due to its link to a severe hypersensitivity reaction (HSR) in 5-8% of patients carrying this allele. Symptoms (fever, rash, organ failure) can be fatal, but screening reduces HSR risk to near-zero (PREDICT-1 trial, NEJM 2008). DHHS guidelines mandate this genetic test, as abacavir's metabolism (via alcohol dehydrogenase) doesn't involve renal function , which is more relevant for tenofovir. Pancreatic enzyme levels aren't monitored pancreatitis is tied to drugs like didanosine, not abacavir. CYP 450 activity is irrelevant abacavir bypasses this pathway. HLA B*5701's specificity to abacavir's safety profile, backed by clinical trials and pharmacogenomics, makes B the critical, evidence-based choice for preventing life-threatening reactions.